- Home
- CRVS vs ESPR Comparison
CRVS vs ESPR Comparison
Compare CRVS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- ESPR
- Stock Information
- Founded
- CRVS 2014
- ESPR 2008
- Country
- CRVS United States
- ESPR United States
- Employees
- CRVS N/A
- ESPR N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- ESPR Health Care
- Exchange
- CRVS Nasdaq
- ESPR Nasdaq
- Market Cap
- CRVS 459.0M
- ESPR 534.3M
- IPO Year
- CRVS 2016
- ESPR 2013
- Fundamental
- Price
- CRVS $7.00
- ESPR $2.60
- Analyst Decision
- CRVS Strong Buy
- ESPR Buy
- Analyst Count
- CRVS 3
- ESPR 6
- Target Price
- CRVS $13.00
- ESPR $6.50
- AVG Volume (30 Days)
- CRVS 789.4K
- ESPR 8.2M
- Earning Date
- CRVS 11-11-2025
- ESPR 11-06-2025
- Dividend Yield
- CRVS N/A
- ESPR N/A
- EPS Growth
- CRVS N/A
- ESPR N/A
- EPS
- CRVS N/A
- ESPR N/A
- Revenue
- CRVS N/A
- ESPR $268,125,000.00
- Revenue This Year
- CRVS N/A
- ESPR $13.05
- Revenue Next Year
- CRVS N/A
- ESPR N/A
- P/E Ratio
- CRVS N/A
- ESPR N/A
- Revenue Growth
- CRVS N/A
- ESPR N/A
- 52 Week Low
- CRVS $2.54
- ESPR $0.69
- 52 Week High
- CRVS $10.00
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- CRVS 58.81
- ESPR 47.71
- Support Level
- CRVS $6.65
- ESPR $2.35
- Resistance Level
- CRVS $7.39
- ESPR $3.41
- Average True Range (ATR)
- CRVS 0.42
- ESPR 0.18
- MACD
- CRVS -0.04
- ESPR -0.03
- Stochastic Oscillator
- CRVS 55.47
- ESPR 9.79
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.